Results 31 to 40 of about 380,300 (294)
Parkinson's disease (PD) is defined by motor symptoms such as tremor at rest, bradykinesia, postural instability, and stiffness. In addition to the classical motor defects that define PD, up to 80% of patients experience cognitive changes and psychiatric
Lindsay E. Stoyka +9 more
doaj +1 more source
Background The development of morphine tolerance is a clinical challenge for managing severe pain. Studies have shown that neuroinflammation is a critical aspect for the development of analgesic tolerance.
Li Wan +9 more
doaj +1 more source
Rho-associated kinase isoform 2 (ROCK2) is an attractive drug target for several neurologic disorders. A critical barrier to ROCK2-based research and therapeutics is the lack of a mouse model that enables investigation of ROCK2 with spatial and temporal ...
Audrey J. Weber +8 more
doaj +1 more source
Pathological α-synuclein recruits LRRK2 expressing pro-inflammatory monocytes to the brain
Background Leucine rich repeat kinase 2 (LRRK2) and SNCA are genetically linked to late-onset Parkinson’s disease (PD). Aggregated α-synuclein pathologically defines PD.
Enquan Xu +15 more
doaj +1 more source
Neuroprotective effects of the immunomodulatory drug FK506 in a model of HIV1-gp120 neurotoxicity. [PDF]
BackgroundHIV-associated neurocognitive disorders (HAND) continue to be a common morbidity associated with chronic HIV infection. It has been shown that HIV proteins (e.g., gp120) released from infected microglial/macrophage cells can cause neuronal ...
Achim, Cristian +9 more
core +1 more source
We identified a systemic, progressive loss of protein S‐glutathionylation—detected by nonreducing western blotting—alongside dysregulation of glutathione‐cycle enzymes in both neuronal and peripheral tissues of Taiwanese SMA mice. These alterations were partially rescued by SMN antisense oligonucleotide therapy, revealing persistent redox imbalance as ...
Sofia Vrettou, Brunhilde Wirth
wiley +1 more source
A manifesto for Alzheimer’s disease drug discovery in the era of disease-modifying therapies
After decades of disappointment, three disease-modifying therapies for Alzheimer’s disease (AD) have been approved since 2021. Burgeoning clinical data on these amyloid β-protein (Aβ) targeting drugs validate the amyloid cascade hypothesis as a molecular
Heike Hering +6 more
doaj +1 more source
Stress granules (SGs) are highly dynamic micromolecular membraneless condensates that generate in cells subjected to stress. Formed from pools of untranslating messenger ribonucleoproteins (RNP), SGs dynamics constitute vital processes essential for cell
Hebatallah Abdelrasol +5 more
doaj +1 more source
Background Each year in the USA, over 2.4 million people experience mild traumatic brain injury (TBI), which can induce long-term neurological deficits.
Michael R. Grovola +8 more
doaj +1 more source
Neurodegeneration in \u3cem\u3eDrop-Dead\u3c/em\u3e Mutant \u3cem\u3eDrosophila melanogaster\u3c/em\u3e Is Associated with the Respiratory System but Not with Hypoxia [PDF]
Mutations in the gene drop-dead (drd) cause diverse phenotypes in adult Drosophila melanogaster including early lethality, neurodegeneration, tracheal defects, gut dysfunction, reduced body mass, and female sterility.
Blumenthal, Edward M +1 more
core +1 more source

